Immune
Safety and efficacy of Thymosin alpha-1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial
Shen Y, Wang XL, Xie JP, et al. · Hepatol Int · 2022
PMID: 35616850 · DOI: 10.1007/s12072-022-10337-4
Summary
Randomized controlled trial of subcutaneous thymosin alpha-1 added to standard care in adults with HBV-related acute-on-chronic liver failure. Endpoints: 90-day transplant-free survival, infection rate.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →Thymosin Alpha-1 5mg28-residue acetylated thymic peptide studied in immune-modulation research.
Guides covering this compound
More Immune citations
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialCrit Care · 2013
- The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trialBMJ · 2025
- Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trialLiver · 1996